Gem Aromatics LimitedQ1 FY27 Results & Financial Update
Gem Aromatics Limited: Q1 FY27 consolidated results and company financials – revenue ₹98.85 Cr, PAT ₹-7.87 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Gem Aromatics price & chart
Market price₹135.23
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Gem Aromatics Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Gem Aromatics reported consolidated revenue from operations of Rs 98.9 crore for Q1 FY27, marking a 12.8% year-on-year increase from Rs 87.6 crore in Q1 FY26 and reflecting improved underlying business activity despite operating in a seasonally softer quarter.
The contraction in consolidated profitability was driven by a combination of higher raw material expenses, unfavourable product mix changes, increased operating costs at newly commissioned facilities, and notably higher non-cash depreciation.
Consolidated depreciation surged to Rs 9.1 crore in Q1 FY27 compared to Rs 1.8 crore in Q1 FY26, directly resulting from the capitalization of a significant portion of the roughly Rs 265 crore greenfield capital expenditure at the Dahej manufacturing plant.
The clove business encountered localized headwinds during the quarter due to floods in Madagascar, which drove up raw material costs and temporarily impacted sales before market conditions normalized.
Management highlighted ongoing progress in customer engagement and product qualifications, particularly for newer product verticals under subsidiary Krystal Ingredients, positioning the platform for progressive commercial scaling in subsequent quarters.
01 · Business model
What does Gem Aromatics do?
Gem Aromatics Limited is a leading Indian manufacturer and exporter of specialty ingredients, focusing on essential oils, aroma chemicals, and value-added derivatives. The company offers a broad portfolio spanning over 80 products across mint, clove, phenol, and natural or synthetic ingredient categories.
The company's products find extensive application across diverse end-use sectors including oral care, personal care, cosmetics, pharmaceuticals, nutraceuticals, and wellness and pain management.
Gem Aromatics operates three manufacturing facilities strategically located in Silvassa (Dadra & Nagar Haveli), Budaun (Uttar Pradesh), and Dahej (Gujarat), supported by an in-house R&D centre in Maharashtra with 13 qualified scientists.
The company serves a global customer base spanning 44 international clients across 20 countries alongside 240 domestic customers, maintaining strong market positions such as being India's largest processor of eucalyptus oil.
02 · Historical context
What shaped the business before this quarter
Incorporated in 1997, the company inaugurated its initial manufacturing facility in Silvassa and subsequently expanded operations by establishing Unit II in Budaun, Uttar Pradesh, in 2016 within the country's prime mint cultivation belt.
Received a strategic investment from dōTERRA Enterprises, Sàrl in 2019 and attained 3-Star Export House status by 2024, reflecting its expanding global footprint and export capabilities.
Successfully completed its initial public offering and listed on BSE and NSE on August 26, 2025, following the initiation of trial production at its greenfield Dahej facility under subsidiary Krystal Ingredients.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹98.85 Cr |
| Total income | ₹99.01 Cr |
| Profit before tax | ₹-8.54 Cr |
| Profit after tax | ₹-7.87 Cr |
| EPS | ₹-1.56 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Consolidated revenue from operations expanded by 12.8% year-on-year to Rs 98.9 crore, driven by healthy underlying demand across established product categories.
The clove business segment experienced sales pressures during the quarter due to supply constraints and higher raw material prices triggered by floods in Madagascar.
The quarter traditionally represents a seasonally softer operating period for certain product lines within the company's portfolio.
What drove margins
Consolidated gross profit margin declined to 16.7% in Q1 FY27 from 29.5% in Q1 FY26, impacted primarily by product mix variations and higher raw material acquisition costs.
Consolidated EBITDA margin narrowed to 3.3% from 17.0% in Q1 FY26, reflecting higher employee expenses of Rs 7.1 crore and operating costs associated with the newly commissioned Dahej facility.
Depreciation expenses jumped sharply to Rs 9.1 crore from Rs 1.8 crore in Q1 FY26 following the capitalization of a significant portion of the ~Rs 265 crore Dahej capex project.
05 · Demand, customers & order book
Where demand is coming from
The company successfully completed customer audits and secured initial commercial orders for cooling agent variants GEM Cool 03, GEM Cool 05, and GEM Cool 23.
Gem Aromatics serves a diversified clientele comprising 240 domestic customers and 44 international customers across 20 countries.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
Remains the largest business segment accounting for approximately 65% of total revenue in FY26, benefiting from strategic proximity to the Budaun mint cultivation belt.
Serves as the second-largest revenue contributor with a strong margin profile, backed by leadership positioning in eugenol processing in India.
Represents emerging high-value chemistry avenues including in-house developed molecules like safranal and damascone targeted at fine fragrances and flavours.
Geography and market mix
The company approved the incorporation of a wholly-owned subsidiary in Brazil during June 2026 to distribute essential oils, aromatic chemicals, and specialty chemicals across Brazil and the broader Latin American market.
Based on FY26 figures, India accounted for 56% of total revenue, followed by the USA at 28%, Brazil at 6%, China at 3%, and the rest of the world contributing 7%.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
The company progressed with the capitalization of its greenfield Dahej facility under subsidiary Krystal Ingredients, representing an investment of approximately Rs 265 crore out of a total planned capex of ~Rs 270 crore.
Operations span three specialized manufacturing sites in Silvassa, Budaun, and Dahej, equipped with advanced technologies including continuous reaction systems and high-vacuum distillation.
Projects, capex and execution
Capital expenditure focused on advancing the Dahej greenfield project, which features next-generation vapor-phase technology and qualifies for a 15% concessional corporate tax rate under government incentives.
08 · Strategy & new businesses
How the company is trying to change its growth mix
The subsidiary is scaling new product lines including cooling agents (revenue contribution expected from Q3 FY27), safranal (revenue contribution expected late Q2 FY27 and more meaningfully in Q3 FY27), and phenol derivatives (trial production expected by end of Q2 FY27 and commercial production targeted in Q3 FY27).
Focusing on high-value specialty molecules such as MEHQ, BHA, guaiacol, 4-MAP, and damascone utilizing effluent-free vapor-phase processes.
09 · Reported developments
What changed operationally
Consolidated revenue from operations grew by 12.8% year-on-year to reach Rs 98.9 crore in Q1 FY27.
Board approval obtained for establishing a wholly-owned subsidiary in Brazil to bolster distribution reach across Latin America.
10 · Pressure points & risks
What is not going smoothly
Higher depreciation and input cost pressures resulted in a consolidated net loss of Rs 7.9 crore for Q1 FY27 compared to a net profit of Rs 8.0 crore in Q1 FY26.
Severe weather conditions in Madagascar disrupted clove supply chains and elevated raw material costs during the quarter.
11 · Management guidance & targets
What management is targeting from here
Management expects revenue contribution from cooling agents (GEM Cool 03, GEM Cool 05, and GEM Cool 23) to commence from Q3 FY27.
Management anticipates revenue contribution from safranal towards the end of Q2 FY27, with more meaningful contributions materializing in Q3 FY27.
12 · Beyond the numbers
What changed beyond the numbers
Reported update
Silvassa Plant Sustainability Rating
The company's Silvassa manufacturing plant received the EcoVadis Platinum sustainability rating.
13 · Key Q&A
The quarter, answered directly
What does Gem Aromatics do?
Gem Aromatics Limited is a leading Indian manufacturer and exporter of specialty ingredients, focusing on essential oils, aroma chemicals, and value-added derivatives. The company offers a broad portfolio spanning over 80 products across mint, clove, phenol, and natural or synthetic ingredient categories.
What is the clearest takeaway from Q1 FY27?
Gem Aromatics reported consolidated revenue from operations of Rs 98.9 crore for Q1 FY27, marking a 12.8% year-on-year increase from Rs 87.6 crore in Q1 FY26 and reflecting improved underlying business activity despite operating in a seasonally softer quarter.
What drove revenue or demand?
Consolidated revenue from operations expanded by 12.8% year-on-year to Rs 98.9 crore, driven by healthy underlying demand across established product categories.
What mattered most for margins or profitability?
Consolidated gross profit margin declined to 16.7% in Q1 FY27 from 29.5% in Q1 FY26, impacted primarily by product mix variations and higher raw material acquisition costs.
What changed operationally beyond the headline numbers?
The company progressed with the capitalization of its greenfield Dahej facility under subsidiary Krystal Ingredients, representing an investment of approximately Rs 265 crore out of a total planned capex of ~Rs 270 crore.
What is management guiding or targeting from here?
Management expects revenue contribution from cooling agents (GEM Cool 03, GEM Cool 05, and GEM Cool 23) to commence from Q3 FY27.
14 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
15 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Cooling Agents Commercialization: Monitor the commercial revenue ramp-up of cooling agent variants GEM Cool 03, GEM Cool 05, and GEM Cool 23 expected from Q3 FY27.
- 02
Brazil Subsidiary Incorporation: Track the formal establishment and operational commencement of the newly approved wholly-owned subsidiary in Brazil.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.